Dutch Biotech Creates Blood To Neutralize Southeast Asia Bird Flu Strains
This article was originally published in PharmAsia News
A Dutch biotechnology firm says it has tested successfully blood it created to neutralize the H5N1 virus based on two major strains found in Vietnam and Indonesia. Crucell said its creation of the specific human monoclonal antibodies could be another way to avoid a feared pandemic of avian influenza. The company said it was able to produce one line of antibodies that neutralized strains found in Hong Kong in 1997, in Vietnam in 2003 and in Indonesia in 2005. (Click here for more
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.